Takeda acquires 13 products from Turkish company Neutec

25 February 2015

Takeda GmbH, the wholly-owned subsidiary of Japanese drugmaker Takeda (TYO: 4502) has signed an agreement to obtain a portfolio of 13 products from Turkish pharma company Neutec.

The acquisition comprises products across gastroenterology, respiratory, metabolic and musculoskeletal indications, from Toplam Kalite, a group company of Neutec in Turkey. It is expected to be finalized in the first quarter of 2015.

Takeda would acquire the select Neutec portfolio in cash for up to 300 million Turkish lira ($121.7 million) including milestone payments. Under the agreement, the products will continue to be manufactured locally by Neutec. This will strengthen Takeda’s position in Turkey, where it has been operating for the past five years, employing more than 130 people in two offices. This acquisition is expected to generate an estimated 100 new jobs in Turkey.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK